These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 33166494)

  • 1. Identification of proteasome inhibitors using analysis of gene expression profiles.
    Mofers A; Selvaraju K; Gubat J; D'Arcy P; Linder S
    Eur J Pharmacol; 2020 Dec; 889():173709. PubMed ID: 33166494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A High-Content Screening Assay for the Discovery of Novel Proteasome Inhibitors from Formosan Soft Corals.
    Ling XH; Wang SK; Huang YH; Huang MJ; Duh CY
    Mar Drugs; 2018 Oct; 16(10):. PubMed ID: 30347865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome Inhibitor Drugs.
    Fricker LD
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():457-476. PubMed ID: 31479618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome deubiquitinases as novel targets for cancer therapy.
    D'Arcy P; Linder S
    Int J Biochem Cell Biol; 2012 Nov; 44(11):1729-38. PubMed ID: 22819849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing.
    Soave CL; Guerin T; Liu J; Dou QP
    Cancer Metastasis Rev; 2017 Dec; 36(4):717-736. PubMed ID: 29047025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis via proteasome inhibition in leukemia/lymphoma cells by two potent piperidones.
    Contreras L; Calderon RI; Varela-Ramirez A; Zhang HY; Quan Y; Das U; Dimmock JR; Skouta R; Aguilera RJ
    Cell Oncol (Dordr); 2018 Dec; 41(6):623-636. PubMed ID: 30088262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
    Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
    Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piperlongumine induces inhibition of the ubiquitin-proteasome system in cancer cells.
    Jarvius M; Fryknäs M; D'Arcy P; Sun C; Rickardson L; Gullbo J; Haglund C; Nygren P; Linder S; Larsson R
    Biochem Biophys Res Commun; 2013 Feb; 431(2):117-23. PubMed ID: 23318177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.
    Cvek B; Dvorak Z
    Curr Pharm Des; 2011; 17(15):1483-99. PubMed ID: 21504411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the ubiquitin+proteasome system in solid tumors.
    Driscoll JJ; Woodle ES
    Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of Natural Proteasome Inhibitors as Novel Anticancer Therapeutics: Current Status and Perspectives.
    Wang H; Yang Q; Dou QP; Yang H
    Curr Protein Pept Sci; 2018 Feb; 19(4):358-367. PubMed ID: 28079010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deubiquitinating enzymes as therapeutic targets in cancer.
    Lim KH; Baek KH
    Curr Pharm Des; 2013; 19(22):4039-52. PubMed ID: 23181570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cadmium pyrithione suppresses tumor growth in vitro and in vivo through inhibition of proteasomal deubiquitinase.
    Chen X; Wu J; Yang Q; Zhang X; Zhang P; Liao S; He Z; Wang X; Zhao C; Liu J
    Biometals; 2018 Feb; 31(1):29-43. PubMed ID: 29098502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curcumin inhibits proteasome activity in triple-negative breast cancer cells through regulating p300/miR-142-3p/PSMB5 axis.
    Liu L; Fu Y; Zheng Y; Ma M; Wang C
    Phytomedicine; 2020 Nov; 78():153312. PubMed ID: 32866906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the ubiquitin proteasome system in haematological malignancies.
    Crawford LJ; Irvine AE
    Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applied techniques for mining natural proteasome inhibitors.
    Stein ML; Groll M
    Biochim Biophys Acta; 2014 Jan; 1843(1):26-38. PubMed ID: 23360979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.
    Narayanan S; Cai CY; Assaraf YG; Guo HQ; Cui Q; Wei L; Huang JJ; Ashby CR; Chen ZS
    Drug Resist Updat; 2020 Jan; 48():100663. PubMed ID: 31785545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Search for Inhibitors of the Ubiquitin-Proteasome System from Natural Sources for Cancer Therapy.
    Tsukamoto S
    Chem Pharm Bull (Tokyo); 2016; 64(2):112-8. PubMed ID: 26833439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.